Home › NDC Lookup › RxCUI directory › RxCUI 1249617

Acetaminophen 300 MG / butalbital 50 MG Oral Tablet — RxCUI 1249617

Name: Acetaminophen 300 MG / butalbital 50 MG Oral Tablet (RxCUI 1249617)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1249617 Semantic clinical drug · SCD ● Current RxNorm concept 8 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1249617

Official nameAcetaminophen 300 MG / butalbital 50 MG Oral Tablet

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asAPAP 300 MG / butalbital 50 MG Oral Tablet

FDA products mapped8

Package NDCs mapped9

Reported Medicaid activity (SDUD)2,666 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Acetaminophen Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Great question. The IV form is used when you can't take medication by mouth — for example, after surgery, if you're nauseated, or if you need faster, more reliable absorption. It d...
Why am I getting acetaminophen through an IV instead of just taking a pill?
Yes, Acetaminophen Injection is approved for children — for pain relief in kids 2 years and older, and for fever reduction in patients of all ages, including premature newborns bor...
The most important things to watch for are signs of a serious allergic reaction — swelling of your face, mouth, or throat, trouble breathing, or hives — and any new skin rash. Eith...

📖 Read our full Acetaminophen Injection guide →

🕸️ Concept Web — How Acetaminophen 300 MG / butalbital 50 MG Oral Tab... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Acetaminophen 300 MG / butalbital 50 MG Oral Tablet RxCUI 1249617 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 3

The active substance itself — no strength, form, or brand attached yet.
- Acetaminophen 161 IN
- Butalbital 19860 IN
- Acetaminophen / butalbital 214178 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Bupap 215777 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Acetaminophen / butalbital Oral Tablet 370514 SCDF
- Acetaminophen / butalbital Oral Product 1152259 SCDG
- Acetaminophen / butalbital Pill 1152260 SCDG
- Acetaminophen / butalbital Oral Tablet [Bupap] 368022 SBDF
- Bupap Oral Product 1168683 SBDG
- Bupap Pill 1168684 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Acetaminophen 300 MG 315261 SCDC
- Butalbital 50 MG 317309 SCDC
- Acetaminophen 300 MG / butalbital 50 MG Oral Tablet [Bupap] 1428622 SBD
- Acetaminophen 300 MG / butalbital 50 MG [Bupap] 1428621 SBDC

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Acetaminophen 300 MG SCDC · 315261
Butalbital 50 MG SCDC · 317309
Acetaminophen / butalbital Oral Tablet SCDF · 370514
Acetaminophen / butalbital Oral Product SCDG · 1152259
Acetaminophen / butalbital Pill SCDG · 1152260

Brand-Name Concepts

Acetaminophen 300 MG / butalbital 50 MG Oral Tablet [Bupap] SBD · 1428622
Acetaminophen 300 MG / butalbital 50 MG [Bupap] SBDC · 1428621
Acetaminophen / butalbital Oral Tablet [Bupap] SBDF · 368022
Bupap Oral Product SBDG · 1168683
Bupap Pill SBDG · 1168684
Bupap BN · 215777

📦 FDA Products & Package NDCs

8 products · 9 package NDCs

9 package NDCs map to RxCUI 1249617 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
35573-0455-02	100 TABLET in 1 BOTTLE (35573-455-02)	BUTALBITAL AND ACETAMINOPHEN	Burel Pharmaceuticals, LLC	2022-12-01
35573-0456-02	100 TABLET in 1 BOTTLE (35573-456-02)	BUTALBITAL AND ACETAMINOPHEN	Burel Pharmaceuticals, LLC	2022-12-01
68682-0306-01	100 TABLET in 1 BOTTLE, PLASTIC (68682-306-01)	Butalbital and Acetaminophen	Oceanside Pharmaceuticals	2017-06-19
69292-0301-01	100 TABLET in 1 BOTTLE (69292-301-01)	BUTALBITAL AND ACETAMINOPHEN	Amici Pharma, Inc.	2026-03-15
69292-0302-01	100 TABLET in 1 BOTTLE (69292-302-01)	BUTALBITAL AND ACETAMINOPHEN	Amici Pharma, Inc.	2026-03-15
69292-0303-01	100 TABLET in 1 BOTTLE (69292-303-01)	BUTALBITAL AND ACETAMINOPHEN	Amici Pharma, Inc.	2026-03-15
70752-0147-10	100 TABLET in 1 BOTTLE, PLASTIC (70752-147-10)	BUTALBITAL and ACETAMINOPHEN	QUAGEN PHARMACEUTICALS LLC	2024-05-01
70752-0147-14	500 TABLET in 1 BOTTLE, PLASTIC (70752-147-14)	BUTALBITAL and ACETAMINOPHEN	QUAGEN PHARMACEUTICALS LLC	2024-05-01
81005-0123-01	100 TABLET in 1 BOTTLE (81005-123-01)	BUTALBITAL AND ACETAMINOPHEN	Aarkish Pharmaceuticals NJ Inc.	2024-12-03

Observed labelers: Amici Pharma, Inc. (3) · Burel Pharmaceuticals, LLC (2) · QUAGEN PHARMACEUTICALS LLC (2) · Aarkish Pharmaceuticals NJ Inc. (1) · Oceanside Pharmaceuticals (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.